Phase 2a Study of IW-9179 to Treat Functional Dyspepsia
Sponsor: Ironwood Pharmaceuticals, Inc.
Terminated
Slow enrollment
Other terminated trials from Ironwood Pharmaceuticals, Inc.
- Bladder Pain Syndrome · Phase PHASE2 · Feb 2025
- Gastroesophageal Reflux Disease (GERD) · Phase PHASE3 · Nov 2020
- Chronic Kidney Disease (CKD) · Phase PHASE4 · Feb 2019
- Irritable Bowel Syndrome Characterized by Constipation · Phase PHASE4 · Oct 2018
More terminations from Ironwood Pharmaceuticals, Inc.
Other Dyspepsia trials with similar outcome
This PHASE2 trial investigates Dyspepsia and Functional Gastrointestinal Disorders and is currently terminated or withdrawn. Ironwood Pharmaceuticals, Inc. leads this study, which shows 6 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Oct 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ironwood Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Almere Stad, Netherlands , Beek, Netherlands , Breda, Netherlands , Bruges, Belgium , Edegem, Belgium , Eindhoven, Netherlands , Genk, Belgium , Ghent, Belgium , Groningen, Netherlands , Leiden, Netherlands and 5 more locations